Abstract
Drug-induced pancreatitis has been rarely reported. Bortezomib is a selective and reversible proteasome inhibitor used for the treatment of patients with multiple myeloma (MM). We describe the case of a patient with multiple myeloma who developed acute pancreatitis after treatment with bortezomib, commonly used in the treatment of this disease. The patient was admitted to the hospital with symptoms of AP. Common etiological factors of AP were all excluded. The patient was later diagnosed as having bortezomib-induced pancreatitis. We reviewed the available medical literature on this topic and found eleven other similar cases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
